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Martin Lauss1,2, Rizwan Haq3, Helena Cirenajwis1,2, Bengt Phung1, Katja Harbst1,2, Johan Staaf1,2,
Frida Rosengren1, Karolina Holm1,2, Mattias Aine1, Karin Jirström1,4, Åke Borg1,2, Christian Busch5,
Jürgen Geisler6,7, Per E. Lønning5, Markus Ringnér1,2, Jillian Howlin1, David E. Fisher3 and Göran Jönsson1,2
The microphthalmia–associated transcription factor (MITF) is a key regulator of melanocyte development and a
lineage-speciﬁc oncogene in melanoma; a highly lethal cancer known for its unpredictable clinical course. MITF
is regulated by multiple intracellular signaling pathways, although the exact mechanisms that determine MITF
expression and activity remain incompletely understood. In this study, we obtained genome-wide DNA
methylation proﬁles from 50 stage IV melanomas, normal melanocytes, keratinocytes, and dermal ﬁbroblasts and
utilized The Cancer Genome Atlas data for experimental validation. By integrating DNA methylation and gene
expression data, we found that hypermethylation of MITF and its co-regulated differentiation pathway genes
corresponded to decreased gene expression levels. In cell lines with a hypermethylated MITF-pathway,
overexpression of MITF did not alter the expression level or methylation status of the MITF pathway genes. In
contrast, however, demethylation treatment of these cell lines induced MITF-pathway activity, conﬁrming that
gene regulation was controlled via methylation. The discovery that the activity of the master regulator of
pigmentation, MITF, and its downstream targets may be regulated by hypermethylation has signiﬁcant
implications for understanding the development and evolvement of melanoma.
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INTRODUCTION
Tumorigenesis is accompanied by diverse genomic and
epigenomic alterations, including somatic mutations, copy
number variations, and changes in DNA methylation patterns.
The signiﬁcance of somatic mutations and copy number
variations has been investigated in melanoma, highlighting
the pattern of UV-induced mutations (Hodis et al., 2012;
Krauthammer et al., 2012). Speciﬁcally, early mutation
screening studies identiﬁed BRAF mutations in a signiﬁcant
fraction of melanoma tumors (Davies et al., 2002). These
ﬁndings subsequently led to the development of targeted
therapies directed toward BRAFV600E-mutated cells (Davies
et al., 2002; Chapman et al., 2011).
Melanomas originate from melanocytes, whichare melanin-
producing cells. Although the bHLHZip microphthalmia–
associated transcription factor (MITF) is the master regulator of
melanin production (pigmentation; Steingrimsson et al.,
2004), early studies also identiﬁed MITF as a lineage-
speciﬁc oncogene in melanoma and found that ampliﬁcation
ofMITF was associated with inferior survival (Garraway et al.,
2005). In addition, rare variants of the MITF gene predispose
to melanoma (Yokoyama et al., 2011). Collectively, these
observations support the idea of a tight connection between
melanocyte differentiation and melanoma initiation and
progression. We have previously shown that melanoma can
be subdivided into at least four gene-expression phenotypes;
one of these phenotypes is characterized by increased MITF
expression and another by high expression of proliferation-
associated genes coupled with decreased expression of MITF
and its downstream targets (Jonsson et al., 2010; Harbst et al.,
2012).
In melanoma, the epigenetic landscape has been previously
investigated and a subset of melanomas with increased CpG
island methylation levels, similar to ﬁndings from other
cancer forms, has been described. This melanoma phenotype
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has been termed the CpG Island Methylator Phenotype
(CIMP) (Weisenberger et al., 2006; Tanemura et al., 2009;
Noushmehr et al., 2010). Conversely, a small number of genes
have shown to be hypomethylated, and thereby activated, in
melanoma (van den Hurk et al., 2012). High-throughput
technology has enabled the screening for biomarkers that
discriminate melanoma from nevi or melanocytes (Furuta
et al., 2006; Koga et al., 2009; Bonazzi et al., 2011; Conway
et al., 2011; Gao et al., 2013, 2014; Li et al., 2013), the
discovery of methylation subgroups (Sigalotti et al., 2012;
Thomas et al., 2014), as well as more dedicated studies (Lian
et al., 2012; Marzese et al., 2013, 2014; Dahl et al., 2014;
Ecsedi et al., 2014).
To further deﬁne genes whose expression is regulated
by DNA methylation in melanomas, we have comprehen-
sively investigated the epigenetic landscape of melanoma
using high-density genome-wide CpG microarrays.
Integrating DNA methylation and gene expression data
highlighted the MITF gene, as tumors with decreased MITF
expression also displayed hypermethylated MITF-associated
CpGs. Importantly, these CpGs were located at the transcrip-
tion start site (TSS) of the melanocyte-speciﬁc transcript
MITF-M. Our ﬁndings reveal the regulation of the MITF
pathway by CpG hypermethylation and highlight the poten-
tial signiﬁcance of epigenetic changes in melanoma
tumorigenesis
RESULTS
DNA methylation patterns in melanoma tumors
We herein describe the epigenetic landscape of melanoma by
analysis of the DNA methylation status of more than 480,000
CpGs in 50 metastatic melanoma tumors (Bergen melano-
mas). To determine the DNA methylation status speciﬁc to
melanoma cells, we measured the DNA methylation in both
cultured melanocytes (light, medium, and dark melanocytes)
and tumors. We deﬁned melanoma-methylated CpGs as
βo0.1 in melanocytes and β40.5 in at least 20% of tumors
and melanoma-hypomethylated CpGs as β40.9 in melano-
cytes and βo0.5 in at least 20% of tumors. A larger fraction of
CpGs were methylated (n= 9,886) rather than hypomethy-
lated (n=5,236) in melanomas.
Hypomethylated CpGs were preferentially located in
intergenic regions and gene bodies and in the “open sea”
(located away from CpG islands). In contrast, hypermethy-
lated CpGs were preferentially located in CpG islands
(Figure 1a). Tumors, in general, had low DNA methylation
levels near the TSS and high methylation levels in gene
bodies, 3′-untranslated regions, and intergenic regions
(Figure 1b). The variation in β-values was considerably
lower for CpGs within 200 bp upstream of the TSS and
for 3′-untranslated regions (Figure 1b). Hence, CpGs upstream
of the TSS were predominantly hypomethylated, whereas
CpGs in 3′-untranslated regions were predominantly
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Figure 1. DNA methylation patterns in melanoma. (a) Location of hypomethylated and hypermethylated CpGs, as well as all platform CpGs in respect to genes
and CpG island annotations (left panel). Functional enrichment of genes that contain hypermethylated CpGs (right panel). For a given set of CpGs (all/hypometh./
hypermeth.), a bar indicates the fraction of CpGs assigned to the respective annotation. TSS1500=1,500 to 201 bp upstream of transcription start,
TSS200=200 bp to transcription start site, Body= gene body. PRC2-targets= set of genes that are targeted by histone H3K27-methylating complex PRC2
(Leeet al. (2006)). (b) DNA methylation characteristics across 50 melanomas; mean of β-values (left) and standard deviation of β-values (right) along the genes.
Meth., methylated.
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hypermethylated. Gene ontology term analysis of hypomethy-
lated CpG-associated genes using DAVID (Huang da et al.,
2009) showed enrichment of genes situated in the plasma
membrane (false discovery rate (FDR)=1× 10− 21) and
involved in system development (FDR= 8× 10− 12). The
hypermethylated CpGs in contrast were overrepresented in
genes that regulate cell differentiation (FDR= 3×10−46), as
well as genes with a Homeobox domain (FDR= 1× 10− 31).
Furthermore, there was a strong preference for developmental
genes (P= 2× 10−73) and embryonic stem cell–derived PRC2
targets (P= 1× 10−216) to be methylated in melanomas
(Figure 1a). PRC2 is a complex with histone methyltransferase
activity and DNA hypermethylation of its target genes in
embryonic stem cells is in agreement with ﬁndings in other
tumor types (Easwaran et al., 2012).
To further validate these ﬁndings, we compared our results
with the DNA methylation status of 244 melanomas from The
Cancer Genome Atlas project (https://tcga-data.nci.nih.gov/
tcga/). Using the same analysis procedure, we found 5,752
hypomethylated CpGs and 10,426 hypermethylated CpGs
that were identical to 76% and 90% of Bergen CpGs,
respectively. Our ﬁndings indicate that aberrant DNA
methylation events in melanomas are reproducible, and in
particular a strong preference for hypermethylation of
developmental genes/PRC2-target genes is observed.
MITF expression is regulated by DNA methylation
The proliferative gene expression phenotype is characterized
by downregulation of immune response and pigment synth-
esis genes (Jonsson et al., 2010). However, the biological
mechanism underlying the expression signature is not fully
investigated. Thus, we aimed to explore DNA methylation
events that correlated with gene expression in melanoma. We
used tumor cohorts with matching genome-wide methylation
and gene expression data to allow us to identify genes whose
expression is primarily regulated by DNA methylation. We
found 2,922 negatively correlated CpGs (Spearman correla-
tiono− 0.39) and 2,406 positively correlated CpGs (correla-
tion 40.39; FDR o0.05), corresponding to 1,119 and 503
unique genes, respectively (Supplementary Table S1 online).
Negative correlation was preferentially observed for CpGs
within 200 bp upstream of TSS and positive correlation for
CpGs within gene bodies (Supplementary Figure S1 online).
Gene ontology terms were not identiﬁed for either positively
or negatively correlated CpGs at FDRo0.01. Notably, among
the genes with a negative correlation between methylation
and gene expression, MITF was highly ranked, having the
44th most negative correlation genome wide. The DNA
methylation status of six CpGs associated with the MITF gene
was coupled to reduced MITF expression in the Bergen
cohort. As expected, the DNA methylations status of these
MITF CpGs was associated with gene expression phenotypes
when using an average β-value across these six CpGs
(P=0.0003, Kruskal–Wallis test). Typically, melanomas of
the pigmentation gene expression phenotype had low
methylation levels coupled to high expression levels of MITF,
whereas melanomas of the proliferative phenotype displayed
the opposite pattern: high methylation levels associated with
low gene expression levels (Figure 2a). In total, 49 CpGs
covering the MITF gene were present on the array. Of the six
CpGs that were signiﬁcantly negatively associated with gene
expression levels ofMITF, three were located at the TSS of the
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Figure 2. Correlation of gene methylation status and gene expression levels in microphthalmia–associated transcription factor (MITF) and MITF targets. For the
CpG with the largest negative correlation value inMITF (a), and its target genesMLANA (b) and TYR (c), β-values are plotted against gene expression values for the
respective gene. In each plot, dots represent individual tumors and are colored according to gene expression phenotype. Methylation levels of light (orange),
medium (dark red), and dark (brown) melanocytes are shown as dashed lines. Below each plot the gene structure and position of each measured CpG is shown.
CpGs with signiﬁcant correlation between methylation and gene expression are labeled red (an asterisk indicates one of the three signiﬁcant CpGs in MLANA).
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M-isoform of MITF (the active isoform in melanocytes and
melanoma cells), whereas three were located within the body
of the MITF-M transcript close to the TSS (Figure 2a).
A detailed analysis of the CpGs covering MITF demonstrated
that the majority of CpGs showed limited variation in
methylation across tumors with the exception of the CpGs
located close to the MITF-M TSS. Speciﬁcally, CpGs located
within the body of the MITF gene were hypermethylated, and
all CpGs located at the TSS of the long isoform were hypo-
methylated across all tumors and normal cells (Figure 3).
Furthermore, genome-wide CpG analysis of three melanocyte
strains, dermal ﬁbroblast, keratinocytes, and lymphocytes
showed similarly consistent results. In normal melanocytes,
the six CpGs located near the MITF-M TSS were all
hypomethylated, whereas in all other normal cells they were
hypermethylated (Figure 3). Subtle differences in methylation
values were observed in the cultured melanocytes with
highest methylation values in the light melanocytes and
lowest in the dark melanocytes. However, it should be noted
that all three strains had very low β-values corresponding to
hypomethylation (Figure 3). Further analysis of the negatively
associated list of CpGs demonstrated that some of these were
located at the TSS of well-known MITF target genes involved
in pigment synthesis such as MLANA and TYR (Figure 3).
MLANA and TYR showed the same pattern as MITF: tumors
with low expression and DNA hypermethylation of the
respective genes were typically of the proliferative phenotype
(Figure 2b and c). Overall, the majority of correlated CpGs,
including the CpGs of MITF and MITF target genes
(Cheli et al., 2010) identiﬁed in the Bergen cohort, were
validated in the The Cancer Genome Atlas cohort as shown
in Figure 4. CpGs located at the TSS of MLANA and TYR
correlated with gene expression, whereas the non-correlated
CpG within the gene body of TYR displayed hyper-
methylation across all tumors, as well as normal cells
(Figure 3). Moreover, MITF target genes unrelated to
pigmentation, such as BCL2 and RAB27A, tended to show
hypermethylation near the TSS in tumor samples with low
mRNA levels of MITF (Figure 3).
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Figure 3. DNA methylation status of microphthalmia–associated transcription factor (MITF) and MITF pathway genes. Tumors in the Bergen and TCGA cohorts
are ordered according to MITF gene expression. MITF and selected MITF target genes are plotted and CpGs are ordered according to genomic position. An
asterisk indicates CpGs with signiﬁcant negative correlation between methylation and gene expression and TSS regions (±1,500 bp from TSS) that include
signiﬁcant CpGs are marked by an orange line. The methylation status for normal cells is also shown. TCGA, The Cancer Genome Atlas data; TSS, transcription
start site.
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MITF pathway hypermethylation in melanoma cell lines
Next, we investigated genome-wide DNA methylation status
of nine melanoma cell lines to determine whether the MITF
pathway hypermethylation is independent of the melanoma
tumor microenvironment. DNA methylation and gene expres-
sion correlation values in the cell line data showed an overlap
of signiﬁcantly correlated CpGs. Importantly, correlations of
CpGs belonging to MITF, MITF targets, and MITF pathway
genes were readily conﬁrmed (Figure 5a). The MITF high-
expressing cell line SK-MEL-5 showed hypomethylation of the
identiﬁed MITF-M CpGs and CpGs in well-known targets of
MITF such as TYR and MLANA. Conversely, the “MITF-low”
cell lines CHL1, WM852, and MM383 showed hypermethy-
lation of these same CpGs, supporting the results obtained
from the tumor cohorts (Figure 5b). Investigating mRNA levels
of the selected MITF target genes (MITF, MLANA, TYR, BCL2,
and RAB27A) across the cell lines, we found that these overall
followed the DNA methylation patterns (Figure 5c). More-
over, immunohistochemistry revealed that the cell lines,
A2058 and HT144, with intermediate MITF expression
consisted of both MITF-positive and MITF-negative cells
(Figure 5d). As methylation levels of some CpGs tended to
be intermediate in these cells, this suggests that some cells are
hypomethylated and some are fully methylated. Finally, we
validated the MITF hypermethylation observed in the mela-
noma cell lines using bisulphite Sanger sequencing (Figure 5b).
Together, this implies that the observed link between DNA
methylation and MITF expression is not dependent on the
tumor microenvironment but instead is established within the
tumor cells.
MITF is not sufﬁcient to modulate DNA hypermethylation in
melanoma
To investigate the nature of the relationship between MITF
expression and DNA methylation, we overexpressed MITF-M
in “MITF-low” cell lines (WM852 and MM383) using a
lentivirus system. These cell lines were selected on the basis
of low levels of MITF mRNA and hypermethylation of CpGs
located at the TSS of MITF-M and MITF target genes
(Figure 5b). 10 days after infection, we conﬁrmed over-
expression of the MITF protein (Figure 6c). We also analyzed
the MITF-M overexpressing cells using the 450K-methylation
arrays. The candidate MITF target and pathway CpGs
remained ﬁrmly methylated. We then selected MLANA as a
well-known MITF target previously shown to be activated by
inducing MITF (Du et al., 2003) and investigated MLANA
mRNA and protein levels (Figures 5c and 6e). As indicated by
the DNA methylation analysis, no increase in MLANA protein
levels was seen, suggesting thatMITF-M alone is not sufﬁcient
to shift the epigenetic program of the MITF differentiation
pathway genes (Supplementary Figure S2 online). This
hypothesis was further supported by gene expression analysis
demonstrating that there is almost no change in expression of
the MITF target genes in these cells (Figure 5c).
Global demethylation treatment reactivates MITF pathway
activity
To evaluate whether DNA methylation blocks MITF expres-
sion in the “MITF-low” cell lines, we induced global
demethylation of the cell lines by 5′-Aza-2′-Deoxycytidine
(5-Aza) treatment for 96 hours. Demethylation was conﬁrmed
by bisulphite Sanger sequencing (Figure 6a). In particular, the
cytosine-to-thymidine ratio decreased when treating cells
with 5-Aza, indicating that demethylation had occurred.
Furthermore, the demethylation treatment was sufﬁcient to
restore MITF protein levels in both cell lines (Figure 6b).
Moreover, the viability of melanoma cells treated with 5-Aza
alone was signiﬁcantly decreased only after 96 hours in both
cell lines (Po0.001, the Mann–Whitney test), whereas the
invasive capacity of the cells was not altered (P40.05, the
Mann–Whitney test; Figure 6c and d). The late effect on cell
viability could suggest that there is a non-speciﬁc toxic effect
of 5-Aza. Furthermore, we found no effect of single agent
BRAF inhibition in the BRAF V600E–positive “MITF-low”
MM383 cell line on viability. Combining 5-Aza and PLX4032
showed a slight additive effect on viability at 96 hours as
compared with either 5-Aza or PLX4032 alone (Po0.01, the
Mann–Whitney Test, Figure 6d).
To further investigate the effect of MITF induction by 5-Aza,
we analyzed the levels of MLANA. No induction of MLANA
levels was observed, suggesting that the 5-Aza induces
MITF-M expression but not MITF-M activity (Figure 6e). To
further establish that the downstream targets of MITF are also
regulated by methylation events, we treated the MITF-M
overexpressing MM383 and WM852 cells with 5-Aza
because these cells would have abundant exogenous MITF-
M to induce MITF target expression if these were regulated by
DNA methylation. Demethylation was conﬁrmed by bisul-
phite Sanger sequencing (Figure 6f). We observed a slight
increase in MITF-M levels, which was accompanied by
restoration of MLANA protein levels (Figure 6e). It should be
noted that MLANA expression is only partially induced by the
exogenous MITF-M. This is demonstrated by the relatively low
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MLANA expression as compared with MLANA levels in
SK-MEL-3 even though only a ﬁfth of the total amount of
SK-MEL-3 protein as compared with the other samples was
loaded on the gel (Figure 6e). Thus, following MITF over-
expression and demethylation treatment, some functional
MITF is produced, albeit at a low level, and can induce low
levels of MLANA.
DISCUSSION
In the current study, we have compared genome-wide DNA
methylation proﬁles from melanoma tumors with normal
melanocytes. The analysis highlighted preferential hyper-
methylation of genes belonging to developmental processes
and PRC2 complex targets; a ﬁnding previously demonstrated
in multiple cancer types (Easwaran et al., 2012). Interestingly,
combining gene expression and DNA methylation data
revealed that a number of genes involved in pigment
synthesis were regulated by hypermethylation, including
MITF and several well-known MITF target genes. MITF is a
master regulator of melanocyte differentiation (Steingrimsson
et al., 2004) and the MITF-M isoform has been shown to
function as a lineage-speciﬁc oncogene, with ampliﬁcation
occurring in approximately 10% of melanomas (Garraway
et al., 2005; Jonsson et al., 2007). Moreover, studies have
shown that genes involved in developmental processes are
kept in relatively stable “on” or “off” states, with tumor
specimens across many cancer types having enforced the
“off” state by DNA methylation (Easwaran et al., 2012). Our
data suggest that key melanocyte genes, such as MITF, are
regulated in such a way. Melanocytes are MITF-“on” cells,
and it is possible that MITF-“off” clones are generated during
tumor evolution. Methylation events during tumor evolution
often occur over many cell divisions and have a stochastic
component (Landan et al., 2012), with different epigenetic
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states leading to diverging tumor cell subpopulations (Sharma
et al., 2010). Hence, it is conceivable that subpopulations of
melanoma cells emerge that have lost all MITF-positive cells
and are therefore “locked” to the MITF-“off” state. Impor-
tantly, a demethylation agent re-induced MITF-M expression
in “MITF-low” cell lines, indicating that demethylation is one
of the factors required to rescue MITF-M expression. Treating
“MITF-low” cell lines that exogenously overexpressed MITF-
M with a demethylating agent led to partial induction of
MLANA, a downstream target of MITF. The lack of strong
MLANA induction, despite high expression of MITF, is con-
sistent with the possibility that post-translational modiﬁcation
of MITF is necessary for its activity as previously described
(Wu et al., 2000; Mansky et al., 2002; Miller et al., 2005;
Murakami and Arnheiter, 2005; Yokoyama et al., 2011;
Vashisht Gopal et al., 2014). Furthermore, these results also
indicate that intrinsically “MITF-low” melanoma cells may be
programed to inactivate MITF-M by post-translational
modiﬁcations and that overexpression of exogenous MITF-M
saturates the post-translational inactivation mechanisms, thus
requiring abundant MITF-M in combination with 5-Aza to
activate downstream targets. Although, further studies are
warranted to determine the post-translational modiﬁcation
state of MITF, our study provide evidence showing that MITF-
M expression and activity can be regulated by DNA
methylation. Importantly, we previously identiﬁed a gene
expression phenotype with decreased mRNA levels of MITF
and MITF target genes, and herein we conclude that this
phenotype may partially be explained by hypermethylation
events. In a recent study, Konieczkowski et al. (2014) found
that “MITF-low” melanoma cells are intrinsically resistant to
MAPK inhibitors. Thus, it is intriguing to speculate that
hypermethylation of the MITF pathway may be a marker of
resistance to MAPK inhibition. Indeed, we showed that the
BRAF V600E-positive MM383 melanoma cell line harboring
MITF-M promoter methylation did not respond to BRAF
inhibition. Furthermore, we also tested the effects of 5-Aza on
melanoma cell viability and invasion. Although, 5-Aza
decreased viability and did not signiﬁcantly affect invasion,
this could be explained by the non-speciﬁc toxic activity of
5-Aza. Because of the complexity of regulation of MITF activity
in melanoma cells, further studies are required to understand
the mechanism of demethylating agents in melanoma.
In summary, we found that the activity of the master regulator
of pigmentation, MITF, may be regulated by hypermethylation,
and this is of fundamental importance for the understanding of
the development and evolvement of melanoma.
MATERIALS AND METHODS
Tumor and cell line cohorts analyzed for methylation patterns
We performed genome-wide methylation analysis using the Illumina
Inﬁnium HumanMethylation450K BeadChip in 50 stage III/IV tumors
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Figure 6. Microphthalmia–associated transcription factor (MITF) expression and activity is regulated by CpG methylation. (a) Bisulphite Sanger sequencing
conﬁrms demethylation of the MITF-M promoter in MM383 and WM852 cells treated with 5 μM 5-Aza. (b) Western blot analysis of MITF-M following 5-Aza
treatment for 96 hours in MM383 and WM852 cell lines. (c) Proliferation and invasion assays showing 5-Aza effects on WM852 cells. The Invasion assay was
performed after 96 hours. (d) Proliferation and invasion assays showing 5-Aza and BRAF inhibition (BRAFi) effects on MM383 cells. Left plot shows proliferative
capacity of MM383 cells treated with 5-Aza, BRAFi, or the combination. Right plot shows invasive capacity of MM383 cells treated with 5-Aza, BRAFi, or the
combination. (e) Western blot analysis of MITF-M and MLANA following 5-Aza treatment for 96 hours in MM383 and WM852 cell lines with and without
exogenous overexpression of MITF-M. As a control, protein lysate from SK-MEL-3 was included. (f) Bisulphite Sanger sequencing conﬁrms demethylation of the
MITF-M promoter in MM383-MITF-M+ and WM852-MITF-M+ cells treated with 5-Aza. Adenosine, green; cytosine, blue; guanine, black; thymidine, red.
5-Aza, 5′-Aza-2′-Deoxycytidine.
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(Supplementary Table S2 online), nine melanoma cell lines, light,
medium, and dark melanocytes, dermal epidermis, ﬁbroblasts
(ScienCell Research, Carlsbad, CA), and peripheral blood leukocytes
(Promega, Madison, WI) (Supplementary Methods online). Written
informed consent was obtained from all patients, and the local ethics
committee approved the study. DNA was extracted as previously
described (Jonsson et al., 2010) and was bisulphite treated using the
EZ DNA Methylation Kit (Zymo, Irvine, CA) according to the
manufacturer’s instructions. Methylation and gene expression data
are available as Gene Expression Omnibus series GSE51547 and
GSE22153, respectively.
Correlation of gene expression and methylation data
For methylation/gene expression correlation analyses CpGs with
methylation levels having standard deviation o0.2 across tumors
were excluded. The remaining features were permuted to obtain a
data driven false discovery rate. This ﬁlter is advisable, as slight
technical variation of β-values can be introduced by copy number
aberrations, which in turn are correlated with gene expression (Lauss
et al., 2012). The matched gene expression data were processed as
previously described (Jonsson et al., 2010), multiple probes of a gene
were median merged, and the 50% most varying genes were kept.
Detailed analysis procedures for the different data sets are described
in Supplementary Information online.
Bisulphite Sanger sequencing, immunohistochemistry, and
western blots
MITF-M was overexpressed using a lentivirus system as pre-
viously described (Haq et al., 2013). Western blot was performed with
antibodies against MITF-M (C5, Thermo Scientiﬁc, Waltham, MA)
and MLANA (EP1422Y, Abcam, Cambridge, UK). DNA primers were
designed to speciﬁcally amplify bisulphite converted genomic DNA
of a distinct region covering the MITF promoter including CpGs
covered by the array. The sequencing products were sequenced
using a 3130XL sequencer. For MITF-M immunohistochemical
analysis, 2 mm sections were automatically pre-treated using the
PT-link system (DAKO, Glostrup, Denmark) and stained in an
Autostainer Plus (DAKO) using a monoclonal MITF-antibody (C5,
Thermo Scientiﬁc, diluted 1:50).
5-Aza treatment, cell viability, and invasion assays
MM383 and WM852 cells were seeded at a density of 9× 103
cells cm− 2 treated 24 hours later with 5 μM 5-Aza. The drug was
replenished every 24 hours for up to 96 hours of treatment (four
pulses) in fresh medium. DNA, RNA, and protein were isolated for
molecular analyses. Cell viability was measured using an AlamarBlue
assay and migration/invasion using the real-time cell analyzer
xCELLigence system (ACEA Biosciences, San Diego, CA). For the
AlamarBlue assay, cells were seeded at a density of 12× 103
cells cm− 2 (4,000 cells per well) in 21 replicates per treatment.
Cells were treated with 5-Aza (5 μM), PLX4032 (200 nM), or 5-Aza
(5 μM)+PLX4032 (200 nM) 24 hours after seeding. The drugs were
replenished every 24 hours for up to 96 hours of treatment (four
pulses) in fresh medium. Statistics were performed using the Mann–
Whitney’s U-test.
For the invasion experiments, melanoma cells were serum starved
prior to cell seeding. Cells were seeded into the upper chamber of the
invasion CIM-plates (4,000 cells per well) in serum-free medium and
treated directly as described for the AlamarBlue assay (3–6 replicates
per treatment). The lower chambers were ﬁlled with (10%) fetal
bovine serum-supplemented medium used as a chemoattractant. Cell
invasion was detected by electric sensors, measuring the impedance
response, on the bottom of the upper chamber while the cells were
penetrating the membrane. Real-time measurements of cell migra-
tion/invasion were performed at 30-minute intervals, and the
impedance responses were interpreted by the real-time cell analyzer
software and converted to cell indices. Statistics were performed
using the Mann–Whitney’s U-test.
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